Actively Recruiting

Phase Not Applicable
Age: 25Years - 50Years
FEMALE
Healthy Volunteers
NCT07550010

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Led by University Hospital, Geneva · Updated on 2026-04-24

1800

Participants Needed

2

Research Sites

104 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Geneva

Lead Sponsor

E

Ecole Polytechnique Fédérale de Lausanne (EPFL), Campus Biotech

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings

CONDITIONS

Official Title

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Who Can Participate

Age: 25Years - 50Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 30 to 49 years who are HIV-negative
  • Women aged 25 to 49 years who are HIV-positive
  • Ability to understand the study procedures and voluntarily provide signed informed consent
Not Eligible

You will not qualify if you...

  • Pregnant at the time of screening
  • Previous hysterectomy
  • Known cervical cancer
  • Symptoms of cervical cancer such as abnormal bleeding or pelvic mass
  • Conditions interfering with cervix visualization
  • Severe pre-existing medical conditions such as advanced cancer or terminal renal failure
  • Inability to comply with the study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Centre Hospitalier Universitaire de Yaoundé

Yaoundé, Cameroon

Actively Recruiting

2

Yaoundé University Teaching Hospital (CHU)

Yaoundé, Cameroon

Actively Recruiting

Loading map...

Research Team

P

Patrick Petignat, Doctor; Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SCREENING

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here